• 1. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007
• 2. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 3. An amorphous lanthanum–iridium solid solution with an open structure for efficient water splitting?
  Wei Sun,Chenglong Ma,Xinlong Tian,Jianjun Liao,Ji Yang,Chengjun Ge,Weiwei Huang J. Mater. Chem. A, 2020,8, 12518-12525
• 4. An aptasensor for the detection of ampicillin in milk using a personal glucose meter
  Xixi Li,Nanwei Zhu,Ruohan Li,Qinpu Zhang Anal. Methods, 2020,12, 3376-3381
• 5. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549

Recent Advances in the Study of {5-phenylspiro2.3hexan-5-yl}methanamine (CAS: 1484379-32-9) and Its Applications in Chemical Biology and Medicine

The compound {5-phenylspiro2.3hexan-5-yl}methanamine (CAS: 1484379-32-9) has recently emerged as a promising scaffold in chemical biology and medicinal chemistry due to its unique spirocyclic structure and potential pharmacological properties. This research brief synthesizes the latest findings on this molecule, focusing on its synthesis, biological activity, and therapeutic applications.

Recent synthetic approaches to 1484379-32-9 have demonstrated improved yields and stereoselectivity through innovative catalytic systems. A 2023 study published in Organic Letters reported a novel palladium-catalyzed [3+2] cycloaddition strategy that achieves 85% yield with >99% enantiomeric purity, addressing previous challenges in stereocontrol during spirocycle formation.

In neuropharmacology, {5-phenylspiro2.3hexan-5-yl}methanamine has shown remarkable activity as a σ1 receptor modulator. Preclinical studies indicate an EC₅₀ of 12.3 nM with 100-fold selectivity over σ2 receptors, suggesting potential applications in neuropathic pain management and neurodegenerative diseases. The compound's ability to cross the blood-brain barrier while maintaining metabolic stability has been particularly noteworthy.

Structural-activity relationship (SAR) studies have revealed that the methanamine moiety is critical for target engagement, while modifications to the phenyl ring can tune receptor subtype selectivity. Computational modeling published in Journal of Medicinal Chemistry (2024) demonstrates how the spirocyclic core induces a unique binding conformation in protein targets.

Emerging applications in radiopharmaceuticals have been explored, with ¹⁸F-labeled derivatives showing promise as PET tracers for imaging σ1 receptor density in vivo. Early-phase clinical trials are anticipated to begin in 2025 based on favorable pharmacokinetic profiles observed in primate studies.

The compound's potential extends beyond CNS applications. Recent high-throughput screening identified 1484379-32-9 derivatives as potent inhibitors of bacterial efflux pumps, with lead compounds showing 8-16 fold enhancement in antibiotic activity against multidrug-resistant Staphylococcus aureus.

Challenges remain in large-scale synthesis and formulation optimization. Current research focuses on developing continuous flow processes to improve production efficiency and investigating prodrug strategies to enhance oral bioavailability, which currently stands at 38% in rodent models.

In conclusion, {5-phenylspiro2.3hexan-5-yl}methanamine represents a versatile scaffold with applications spanning neuroscience, infectious disease, and diagnostic imaging. The coming years are likely to see increased translational research efforts as its unique pharmacological profile continues to be elucidated.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)